Use of ACTIMMUNE in Patients With ADO2

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

November 12, 2019

Study Completion Date

November 12, 2019

Conditions

Autosomal Dominant Osteopetrosis Type 2

Interventions

DRUG

ACTIMMUNE

Trial Locations (1)

Indiana University School of Medicine, Indianapolis

All Listed Sponsors

collaborator

Horizon Pharma Ireland, Ltd., Dublin Ireland

INDUSTRY

lead

Indiana University

OTHER

NCT02584608 - Use of ACTIMMUNE in Patients With ADO2 | Biotech Hunter | Biotech Hunter